rights to certain technologies in the
diagnostics market. As a result, the company recorded a $35 million
gain and an $18.9 million research and development charge in connection
with this settlement in the second quarter of 2006.
k) Debt Extinguishment -- On June 1, 2006, approximately $56 million of
the company's $100 million debentures were tendered by the holders of
the debentures. In connection with this redemption the company
incurred approximately $2.7 million in debt extinguishment costs in the
l) Agencourt Personal Genomics ("APG") -- In July 2006, the company sold
its non-controlling interest in APG. The company received
approximately $50 million in cash and recognized a gain from the sale.
This gain and the company's share of APG's operating results are
included in discontinued operations. In connection with the sale an
additional $6.0 million was held in escrow. In July 2007, pursuant to
the terms of the sale agreement, the company received its $2.6 million
proportional share of the $6.0 million. The additional gain on sale of
$2.6 million ($1.6 million, net of taxes) was recorded in
discontinued operations for the third quarter ended 2007.
Beckman Coulter, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP Net Earnings to Adjust Earnings Before Interest, Taxes, Depreciation & Amortization ("Adjusted EBITDA")
Trailing 12 Months Trailing 12 Months
September 30, 2007 December 31, 2006
Net earnings for the fir
|SOURCE Beckman Coulter, Inc.|
Copyright©2007 PR Newswire.
All rights reserved